Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05783869

Study of Bronchiectasis and Associated Cardiovascular Comorbidities

Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Bronchiectasis Bronchial Diseases Respiratory Tract Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Assiut unviresty - Faculty of Medicine

Asyut, 71511, Egypt

Location status: Recruiting

Location contact

Ahmad Shaddad, Lecturer

CONTACT

[email protected]

+201111171930

About this study

The study will include patients with bronchiectasis, and in an attempt to correlate the effect and burden of cardiovascular comorbidities in those patients, we will study the quality of life in those patients in comparison to the control group ( patients with bronchiectasis and without any other comorbidities) using SF-36 quality of life questionnaire. We will also study the inflammatory markers in both groups using D-dimer, BNP, and CRP and correlate them with the frequency of hospital admission, the severity of symptoms, and the general health state.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period.

Exclusion criteria

  • Any Patients who refuse to participate in the study.
  • Any other comorbidity or end-organ failure may affect the study's result.

Treatment and study plan

Echocardiography

Device

echocardiographic study of both groups

Other names: Pulmonary function test, Routine laboratory investigations and inflammatory markers

Primary outcomes

  1. assessment of BNP (Brain natriuretic peptide) pg/ml levels in patients with bronchiectasis and cardiovascular comorbidities.

    Time frame: March 2023 to September 2023

    Serum BNP (Brain natriuretic peptide) pg/ml will be compared in both groups.

  2. Assessment of Quality of life in patients and control groups using The Short Form (36) Health Survey (SF-36)

    Time frame: March 2023 to September 2023

    The Short Form (36) Health Survey will be performed in both groups. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Secondary outcomes

  1. Hospitalization frequency in patient group compared to control group.

    Time frame: March 2023 to September 2023

    Number of hospital admission in the last year will be compared in both groups.

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmad Shaddad, MD

CONTACT

[email protected]

+201111171930

Shaadad Shaddad, MD

CONTACT

[email protected]

+201111171930

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Collaborators

  • Aliae AR Mohamed Hussein [ahussein

Registry information

Official study title

Effect of Cardiovascular Comorbidities on Disease Severity and Quality of Life in Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Mar 24, 2023
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.